Maipl Therapeutics develops small molecule FP antagonists that selectively inhibit prostaglandin F2α signaling, targeting conditions such as cancer, endometriosis, and idiopathic pulmonary fibrosis. Their approach addresses the dysregulation of prostaglandin pathways, offering safer treatment options with minimal side effects compared to traditional NSAIDs and COX-2 inhibitors.
Funding
$135K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for conditions like cancer, endometriosis, and idiopathic pulmonary fibrosis (IPF) often involve non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, which can lead to gastrointestinal, renal, and cardiovascular side effects. Existing therapies may also lack the specificity needed to effectively target the underlying causes of these diseases. This creates a need for safer and more targeted therapeutic options.
Solution
Maipl Therapeutics is developing a platform of first-in-class, small molecule FP antagonists that selectively inhibit prostaglandin F2α (PGF2α) signaling, a key driver in diseases such as cancer, endometriosis, and IPF. Their approach focuses on precision therapies that address the dysregulation of prostaglandin pathways without affecting other essential prostaglandin functions. By selectively targeting the PGF2α pathway, Maipl's antagonists aim to provide safer and more effective treatments compared to traditional NSAIDs and COX-2 inhibitors. The lead compound, MA-0838, is being developed as a (neo)adjuvant therapy to augment chemo, radiation, or immunotherapies, with the goal of improving survival rates and overcoming resistance. Other FPA assets are also in development for indications where elevated F2α signaling is a driver.
Target Audience
The primary target audience includes patients suffering from cancer, endometriosis, and idiopathic pulmonary fibrosis, as well as oncologists, gynecologists, and pulmonologists seeking safer and more effective treatment options.
Features
- Potent and highly selective small molecule antagonists of the PGF2α pathway.
- Over 100x selectivity for the PGF2α pathway over other prostaglandin pathways.
- Demonstrated high potency in inhibiting the PGF2α pathway in rodents and humans at sub-nanomolar concentrations.
- Excellent pharmacokinetics (PK) profile suitable for oral administration.
- Clean safety profile based on extensive in vitro assessments.
- Preclinical efficacy and differentiation potential demonstrated in in vitro, ex vivo (human), and in vivo (animal) models.
- Lead compound MA-0838 targeting cancer (neo)adjuvant therapy.
- Additional programs targeting endometriosis (MA-7107) and idiopathic pulmonary fibrosis (MA-4604).